Swiss oncology giant Roche (ROG: SIX) has broken new ground in the UK, with the first ever approval for a subcutaneous version of its checkpoint blocker Tecentriq (atezolizumab).
The new formulation, which takes around seven minutes to administer, will offer a considerably more patient-friendly option for patients. The current intravenous infusion takes up to an hour to be administered.
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has provided marketing authorization for the product in all currently-approved indications, including certain types of lung, bladder, breast and liver cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze